A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs

Exclusion Criteria

• •Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at Screening
• •Serum ALT or AST \>2X ULN
• •Subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (CVA) within 6 month of the Screening Visit; or sick sinus syndrome or second or third degree atrioventricular block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia
• •Implanted cardioverter defibrillator (ICD) that has fired for any arrhythmia within 3 months of Screening or implanted pacemakers
• •Symptomatic CHF requiring treatment
• •Hemodynamically significant valvular heart disease
• •Hemodialysis or peritoneal dialysis; or history of renal transplant
• •Diagnosis or recurrence of malignancy within the past 3 years
• •Sleep apnea
• •Subjects who perform alternating shift or night work
• •Subjects who have participated in a clinical study involving another investigational drug or device within 1 month of the Screening Visit